Nanostring Breast Cancer 360 Research Panel

NanoString Technologies has launched the Breast Cancer 360T (BC 360) research panel, which provides a multimodal analysis of tumor gene expression, microenvironment, and immune response. The 770-gene expression panel is the second in a series of 360 panels, following NanoString's PanCancer Immuno-Oncology 360 panel that was launched last year. It includes content across important breast cancer pathways and validated signatures including NanoString's PAM50 signature for breast cancer subtyping and its Tumor Inflammation Signature, as well as other targets involved in DNA damage repair deficiency, inhibitory immune signaling, and immune cell population abundance.